Overview

Mixed Antagonist of Serotonin for Claudication Optimal Therapy

Status:
Completed
Trial end date:
2007-12-01
Target enrollment:
Participant gender:
Summary
To investigate in patients suffering from intermittent claudication due to Fontaine stage II PAD whether a 24-week treatment by SL650472 OD on top of clopidogrel may result in an improvement of walking capacity, by comparing three doses of SL650472 to placebo, and to calibrate such effect versus cilostazol
Phase:
Phase 2
Details
Lead Sponsor:
Sanofi
Treatments:
Clopidogrel